Novo Nordisk A/S (NVO) — closed signal from March 28, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 26, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$35.00 – $36.80Entry zone — fair-value band
$36.04Published — price the day we called it
$41.45Target — the price the thesis aimed for
$48.50Peak — highest point inside the window, not a realized return
$48.07Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 30 days.
Peak price
$48.50
peak on June 26, 2026 — not a realized returnPeak gain
+34.6%
peak, from the publication priceWindow close
$48.07
end-of-window price, context onlyDays to target
30
Window
March 28, 2026 – June 26, 2026
The thesis — published March 28, 2026
Predicted growth
+15%
over the measurement windowTarget price
$41.45
the price the thesis aimed forEntry zone
$35.00 – $36.80
the fair-value band we waited forPrice at publication
$36.04
published March 28, 2026Confidence
78%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk could stage a short-term recovery after a big drop in sentiment. The FDA approval of a once-weekly insulin gives a clear new reason for interest, and the stock's price is far below its prior trend. Growth is slower now, so the opportunity is cautious, but profitability and the defensive healthcare profile help the rebound case.
Primary drivers
- FDA approval gives a clear near-term product reason for renewed interest
- Healthcare demand helps limit downside in uncertain markets
- Lower price versus prior trend creates room for a bounce
- Early signs of momentum repair suggest a short-term recovery attempt
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.